Less than 20% of patients in Japan interested in new Alzheimer’s drugs received one
Many were ineligible or decided against taking the medications due to potential side effects and the high cost, a study has found.
Original Source
Read the full article at Japantimes →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.